Vermillion Sets Second Quarter 2013 Conference Call for Wednesday, August 14, 2013

Vermillion Sets Second Quarter 2013 Conference Call for Wednesday, August 14,
                                     2013

PR Newswire

AUSTIN, Texas, July 31, 2013

AUSTIN, Texas, July 31, 2013 /PRNewswire/ --Vermillion, Inc. (NASDAQ: VRML),
a multivariate diagnostics company focused on gynecologic cancers and women's
health, will hold a conference call on Wednesday, August 14, 2013, at 4:30
p.m. Eastern time to discuss results for the second quarter ended June 30,
2013. Financial results will be issued in a press release prior to the call.

Vermillion's President and CEO Thomas McLain will host the call, followed by a
question and answer period.

Date: Wednesday, August 14, 2013
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-800-732-5617
International: 1-212-231-2906
Conference ID: 21668439
Webcast: http://www.media-server.com/m/p/v7m7pi5y

The conference call will be webcast live and available for replay via the
investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start
time. An operator will register your name and organization. If you have any
difficulty connecting with the conference call, please contact Liolios Group
at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call
through August 28, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay ID: 21668439

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in oncology and
women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical
assessment of tumors for malignancy, using a unique multi-biomarker approach.
In a published clinical trial, OVA1 achieved 99% sensitivity in detecting
epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I
EOC, the earliest and curable EOC stage, compared with 57% for the
conventional biomarker CA125. In addition, OVA1 found 82% of malignancies
missed by non-specialist pre-surgical assessment, and it increased detection
of malignancy over ACOG guidelines from 77% to 94%. As the first
protein-based, In Vitro Diagnostic Multivariate Index Assay (IVDMIA) cleared
by the FDA, OVA1 also represents a new class of software-based diagnostics.
Additional information about these published clinical trials is available on
Vermillion's website at www.vermillion.com.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
vrml@liolios.com

SOURCE Vermillion, Inc.

Website: http://www.vermillion.com
 
Press spacebar to pause and continue. Press esc to stop.